ClinicalTrials.gg
CompletedNCT00559585Updated Nov 9, 2015Results posted

Methotrexate-Inadequate Response Study

A Phase 3 interventional study of Subcutaneous (SC) Abatacept and Intravenous (IV) Abatacept in Rheumatoid Arthritis (RA), sponsored by Bristol-Myers Squibb. Completed at 204 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-09.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,492
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
Largest of 63
2,492 · median 119
Started
2008
with 2 others
Phase 3
26 of 63
2 open now
Registered
19th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one has the largest enrollment, is one of 3 that started in 2008, is one of 26 in phase 3, and was the 19th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Subjects who are considered methotrexate inadequate responders
  • 10 or more swollen joints (66 joint count) and 12 or more tender joints (68 joint count)

Exclusion criteria

Exclusion Criteria:

  • Subjects who failed one or multiple anti-tumor necrosis factor (TNF) therapies
  • Subjects who meet diagnostic criteria for any other rheumatic disease (e.g., lupus erythematous)
  • Subjects with active vasculitis of a major organ system (except for subcutaneous rheumatoid nodules)
  • Subjects with severe chronic or recurrent bacterial infections
  • Subjects who have received treatment with rituximab

An Anti-TNF Failure Sub-study was initiated (recruited separately from Main study) using the same treatment as the Main study in order to assess the immunogenicity and safety in the Anti-TNF Failure population. The Sub-study terminated due to low recruitment and participants were permitted to roll into the LT Open Label Period.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,492 participants (actual)

Study arms

  • Active comparator
    Subcutaneous (SC) Abatacept

    Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.

    Drug: Subcutaneous (SC) Abatacept

  • Active comparator
    Intravenous (IV) Abatacept

    Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).

    Drug: Intravenous (IV) Abatacept

Interventions

  • Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.

    Also known as: Orencia, BMS-188667

  • Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo). 500mg (for body weight up to 60 kg) 750 mg (body weight between 61 and 100 kg) 1g (body weight above 100 kg)infusions

    Also known as: Orencia, BMS-188667

06

What researchers measure

Primary outcomes

  1. Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169

    The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).

    Time frame: Day 169

  2. Anti-TNF Failure Sub-Study Double Blind Period : Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Response in Anti-TNF Failure Population

    Serum samples from all treated adult participants with active rheumatoid arthritis who were from the Anti-TNF failure population were screened for the presence of drug-specific antibodies using Enzyme Linked Immunoabsorbant Assay (ELISA). The number of participants who had the presence of anti-abatacept antibodies or anti-CTLA-4 antibodies present in their serum are summarized.

    Time frame: Days 85, and 169 and postvisits on Days 28, 56, and 85

Secondary outcomes

  1. Double-blind Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Day 169

    The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein). ACR 70 is defined similarly with 70% improvements from baseline for tender and swollen joint counts and 3 out of 5 core measures.

    Time frame: Day 169

  2. Double-blind Period: Mean Baseline Health Assessment Questionnaire Disability Index (HAQ-DI) for Participants With Assessments at Day 169

    The disability section of the full HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. Higher scores=greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered.

    Time frame: Day 169

  3. Double-blind Period: Adjusted Mean Change From Baseline to Day 169 in HAQ-DI

    The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0.

    Time frame: Baseline to Day 169

  4. Double-blind Period: Number of Participants Achieving Clinically Meaningful HAQ-DI Response at Day 169

    The disability section of the full HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3=unable to do. Higher scores=greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ-DI response=an improvement of at least 0.3 units from baseline in HAQ-DI.

    Time frame: Day 169

  5. Double-blind Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, or AEs Leading to Discontinuation

    AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug

    Time frame: Day 1 to 56 days after last dose in short-term or first dose in the long-term, whichever occurs first.

  6. Anti-TNF Failure Sub-study Double-blind Period: Number of Participants With SAEs, AEs Leading to Discontinuation or Who Died

    AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

    Time frame: Day 1 to 56 days after last dose in short-term or first dose in the long-term, whichever occurs first.

  7. Double-blind Period: Number of Participants With AEs of Special Interest

    AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs: all infections,serious infections,and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (prespecified AEs occurring within 1 hr of start of infusion), peri-infusional AEs (prespecified AEs occurring within 24 hrs of the start of infusion), system injection reactions, and local injection site reactions

    Time frame: Day 1 up to 56 days post last dose in short- term period or first dose in the long -term period, whichever occurs first.

  8. Double-blind Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements

    Vital sign measurements were performed for participants before and after infusion/subcutaneous injection of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.

    Time frame: Day 1 through end of short-term period (Day 169)

  9. Double-blind Period: Number of Participants With Hematology Laboratory Test Results Meeting the Criteria for Marked Abnormality

    ULN=upper limit of normal; LLN=lower limit of normal; BL= baseline. Marked abnormality criteria: Hemoglobin: \>3 g/dL decrease from BL; hematocrit: \<0.75\*BL; erythrocytes: \<0.75\*BL; platelets: \<0.67\*LLN/\>1.5\*ULN, or if BL\<LLN, use \<0.5\*BL and \<100,000 mm\^3; leukocytes: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN use \<0.8\*BL or \>ULN, or if BL\>ULN, use \>1.2\*BL or \<LLN; neutrophils+bands: \<1.0\*10\^3 c/uL; eosinophils: \>0.750\*10\^3 c/uL; basophils: \>400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750\*10\^3 c/uL/\>7.50\*10\^3 c/uL.

    Time frame: Day 1 through end of short-term period (Day 169)

  10. Double-blind Period: Number of Participants With Liver Function Laboratory Test Results Meeting the Criteria for Marked Abnormality

    Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\*ULN, or if BL\>ULN, use \>3\*BL; aspartate aminotransferase (AST): \>3\*ULN, or if BL\>ULN, use \>4\*BL; alanine aminotransferase (ALT): \>3\*ULN, or if BL\>ULN, use \>4\*BL; G-glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN, use \>3\*BL; bilirubin: \>2\* ULN, or if BL\>ULN, use \>4\*BL; blood urea nitrogen: \>2\* BL; creatinine: \>1.5\*BL

    Time frame: Day 1 through end of short-term period (Day 169)

  11. Double-blind Period: Number of Participants With Electrolyte Laboratory Test Results Meeting the Criteria for Marked Abnormality

    Marked abnormality criteria: Sodium: \<0.95\*LLN/\>1.05\*ULN, or if BL\<LLN, use \<0.95\* BL or \>ULN, or if BL\>ULN, use\>1.05\* BL or \<LLN; potassium: \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN, use\>1.1\* BL or \<LLN; chlorine: \<0.9\*LLN/\>1.1\* ULN, or if BL\<LLN, use \<0.9\*BL or \>ULN, or if BL\>ULN, use\>1.1\*BL or \<LLN; calcium: \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN, use \<0.75\*BL or \>ULN, or if BL\>ULN, use\>1.25\* BL or \<LLN; phosphorous: \<0.75\* LLN/\>1.25\*ULN, or if BL\<LLN, use 0.67\*BL or \>ULN, or if BL\>ULN, use\>1.33\* BL or \<LLN

    Time frame: Day 1 through end of short-term period (Day 169)

  12. Double-blind Period: Minimum Observed Serum Concentration of Abatacept

    Time frame: Days 57, 85, 113, 120, 127, 134, 141, and 169

  13. Anti-TNF Failure Sub-study Double-blind Period: Minimum Observed Serum Concentration (Cmin) of Abatacept

    Serum concentrations of abatacept were analyzed using a validated ELISA. Steady-state trough observed concentration in serum (Cminss) was measured in μg/mL. Samples were obtained on Days 57, 85, 113, 120, 127, 134, 141, and 169.

    Time frame: Days 57, 85, 113, 120, 127, 134, 141, and 169 (ST Period)

  14. Double-blind Period: Maximum Observed Serum Concentration of Abatacept

    Time frame: End of infusion on Days 1 and 113 for IV infusion and in the dosing interval of Days 113 to 120 for subcutaneous

  15. Anti-TNF Failure Substudy Double Blind Period: Geometric Mean Maximum Observed Serum Concentration of Abatacept

    Serum concentrations of abatacept were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). Samples were obtained on Days 57, 85, 113, 120, 127, 134, 141, and 169. Cmax was measured in micrograms per milliliter (μg/mL).

    Time frame: End of infusion on Days 1 and 113 for IV infusion and in the dosing interval of Days 113 to 120 for subcutaneous

  16. Double-blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept

    Time frame: Dosing interval between Days 113 and 141 (TAU=28 days)

  17. Anti-TNF Failure Sub-study Double Blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept

    Serum concentrations of abatacept were analyzed using a validated ELISA. AUC(TAU) was measured as μg\*h/mL. Samples for AUC (TAU) were obtained on Days 113, 120, 127, 134, and 141.

    Time frame: Dosing Interval between Days 113 and 141 (TAU=28 days)

  18. Double-blind Period: Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Responses Over Time by Enzyme Linked Immunoabsorbant Assay (ELISA)

    Serum samples from all treated adult participants with active rheumatoid arthritis were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept (anti-ABA) or anti-CTLA4 antibody (anti-CTLA4).

    Time frame: Days 85, and 169 and postvisits on Days 28, 56, and 85

  19. Double-blind Period: Time-matched Median Percent Change From Baseline in Levels of Serum C-reactive Protein Over the Short-term Period

    C-reactive protein is an acute phase reactant protein that is a clinical marker for rheumatoid arthritis. Time-matched median percent change from baseline= (time-matched baseline value - Post-baseline value)/time-matched baseline value\*100, where the time-matched baseline value represents the median baseline value for only that cohort of participants with measurements available at that visit.

    Time frame: Baseline to Days 15, 29, 57, 85, 113, 141, and 169

  20. Double-blind Period: Number of Participants With Positive Anti-abatacept Responses Over Time by Electrochemiluminescence Immunoassay Among the First 10% of Participants Randomized

    An electrochemiluminescence immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; abatacept molecule). Ig and/or Junction (JNCT) category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a postbaseline titer higher than Baseline, or any postbaseline positivity if Baseline value was missing. Trt=treatment.

    Time frame: Days 85, and 169 and postvisits on Days 28, 56, and 85

  21. Double-blind Period: Number of Participants Seroconverting by Day 169 According to Status (Negative or Positive) at Baseline

    Rheumatoid factor (RF) is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process.

    Time frame: Baseline to Day 169

  22. Open-Label LT Period: Number of Participants Achieving ACR 20 Response at Days 169, 729, 1261, and 1821

    The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).

    Time frame: Days 169, 729, 1261, 1821

  23. Open-Label LT Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Days 169, 729, 1261, 1821

    The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein). ACR 70 is defined similarly with 70% improvements from baseline for tender and swollen joint counts and 3 out of 5 core measures.

    Time frame: Days 169, 729, 1261, 1821

  24. Open-Label LT Period: Mean Change From Baseline in Disease Activity Score in 28 Joints (DAS28) Using C-reactive Protein (CRP) at Days 169, 729, 1261, 1821

    The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6. A clinically significant response= decrease in DAS28 score of \>1.2 from baseline.

    Time frame: Days 169, 729, 1261, 1821

  25. Open-Label LT Period: Number of Participants Achieving DAS 28 Remission at Days 169, 729, 1261, 1821

    The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6.

    Time frame: Days 169, 729, 1261, 1821

  26. Open-Label LT Period: Number of Participants Achieving DAS 28 Low Disease Activity (LDA) at Days 169, 729, 1261, 1821

    The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6.

    Time frame: Days 169, 729, 1261, 1821

  27. Open-Label LT Period: Number of Participants With HAQ-DI Response at Days 169, 729, 1261, 1821

    The disability section of the full HAQ includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. HAQ-DI overall score ranges from a minimum of 0 to a maximum of 3.0. HAQ response was defined as an improvement (reduction) from baseline (Day 1) of at least 0.3 units in the HAQ score.

    Time frame: Days 169, 729, 1261, 1821

  28. Open-Label LT Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, or AEs Leading to Discontinuation

    AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug

    Time frame: End of ST Period (Day 169) to last dose plus 85 days, up to 5 years (September 2014)

  29. Open-Label LT Period: Number of Participants With AEs of Special Interest

    AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs: all infections, serious infections, and opportunistic infections; autoimmune disorders; malignancies; system injection reactions, and local injection site reactions.

    Time frame: End of ST Period (Day 169) to last dose plus 85 days, up to 5 years (September 2014)

  30. Open-Label LT Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements

    Vital sign assessments were performed in the LT period at 12-week intervals and at a yearly visit (at 16-week intervals) and, for participants who withdrew from the study prematurely, 7 days after the last dose of SC abatacept. Vital signs included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.

    Time frame: End of ST Period (Day 169) to last dose plus 7 days, up to 5 years (September 2014)

  31. Open-Label LT Period: Number of Participants With Clinically Significant Laboratory Abnormalities

    Laboratory assessments were performed in the LT period at 12-week intervals and at a yearly visit and, for participants who withdrew from the study prematurely, 7 days after the last dose of SC abatacept. Abnormalities were determined to be clinically significant by the investigator.

    Time frame: End of ST Period (Day 169) to last dose plus 7 days, up to 5 years (September 2014)

07

Results

Posted Jul 6, 2011

Participant flow

During the double blind short term (ST) period of the Main study, a sub-study in RA participants was initiated to evaluate anti-tumor necrosis factor (TNF) failure population. The sub-study was terminated early due to slow recruitment and participants from the sub-study were allowed to roll into the Main study during the LT Open Label Period.

Double Blind ST Period Main Study
Participant flow — Double Blind ST Period Main Study
MilestoneSubcutaneous (SC) AbataceptIntravenous (IV) Abatacept
Started736721
Completed693676
Not completed4345
Withdrew: Adverse event1725
Withdrew: Withdrawal by subject115
Withdrew: Lost to follow-up06
Withdrew: Administrative reason by sponsor10
Withdrew: Death11
Withdrew: No longer meets study criteria21
Withdrew: Lack of efficacy61
Withdrew: Poor/non-compliance30
Withdrew: Missed doses01
Withdrew: Incomplete breast exam01
Withdrew: Suspended drug due to surgery01
Withdrew: Early discontinuation01
Withdrew: Participant weight gain10
Withdrew: Participant withdrew-recurrent infection01
Withdrew: Investigator decision01
Withdrew: Ongoing infection risk10
Anti-TNF Sub-Study in ST Period
Participant flow — Anti-TNF Sub-Study in ST Period
MilestoneSubcutaneous (SC) AbataceptIntravenous (IV) Abatacept
Started810
Completed79
Not completed11
Withdrew: Lack of efficacy11
Open Label LT Period Main + Sub-Study
Participant flow — Open Label LT Period Main + Sub-Study
MilestoneSubcutaneous (SC) AbataceptIntravenous (IV) Abatacept
Started13730
Completed9450
Not completed4280
Withdrew: Adverse event1000
Withdrew: Withdrawal by subject810
Withdrew: Pregnancy160
Withdrew: Lost to follow-up320
Withdrew: Administrative reason by sponsor90
Withdrew: Death200
Withdrew: No longer met criteria10
Withdrew: Lack of efficacy890
Withdrew: Poor/non-compliance80
Withdrew: Non-specified710
Withdrew: No end of study status page10

Outcome measures

PrimaryDouble-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169

The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).

Time frame:
Day 169
Reported as:
Number · participants
Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169
participantsSubcutaneous AbataceptIntravenous Abatacept
Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169527514
SecondaryDouble-blind Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Day 169

The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein). ACR 70 is defined similarly with 70% improvements from baseline for tender and swollen joint counts and 3 out of 5 core measures.

Time frame:
Day 169
Reported as:
Number · participants
Double-blind Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Day 169
participantsSubcutaneous AbataceptIntravenous Abatacept
ACR 50357341
ACR 70183170
SecondaryDouble-blind Period: Mean Baseline Health Assessment Questionnaire Disability Index (HAQ-DI) for Participants With Assessments at Day 169

The disability section of the full HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. Higher scores=greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered.

Time frame:
Day 169
Reported as:
Mean · units on a scale
Double-blind Period: Mean Baseline Health Assessment Questionnaire Disability Index (HAQ-DI) for Participants With Assessments at Day 169
units on a scaleSubcutaneous AbataceptIntravenous Abatacept
Double-blind Period: Mean Baseline Health Assessment Questionnaire Disability Index (HAQ-DI) for Participants With Assessments at Day 1691.72 ± 0.681.67 ± 0.67
SecondaryDouble-blind Period: Adjusted Mean Change From Baseline to Day 169 in HAQ-DI

The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0.

Time frame:
Baseline to Day 169
Reported as:
Mean · units on a scale
Double-blind Period: Adjusted Mean Change From Baseline to Day 169 in HAQ-DI
units on a scaleSubcutaneous AbataceptIntravenous Abatacept
Double-blind Period: Adjusted Mean Change From Baseline to Day 169 in HAQ-DI-0.69 ± 0.02-0.70 ± 0.02
SecondaryDouble-blind Period: Number of Participants Achieving Clinically Meaningful HAQ-DI Response at Day 169

The disability section of the full HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3=unable to do. Higher scores=greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ-DI response=an improvement of at least 0.3 units from baseline in HAQ-DI.

Time frame:
Day 169
Reported as:
Number · participants
Double-blind Period: Number of Participants Achieving Clinically Meaningful HAQ-DI Response at Day 169
participantsSubcutaneous AbataceptIntravenous Abatacept
Double-blind Period: Number of Participants Achieving Clinically Meaningful HAQ-DI Response at Day 169483442
SecondaryDouble-blind Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, or AEs Leading to Discontinuation

AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug

Time frame:
Day 1 to 56 days after last dose in short-term or first dose in the long-term, whichever occurs first.
Reported as:
Number · participants
Double-blind Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, or AEs Leading to Discontinuation
participantsSubcutaneous AbataceptIntravenous Abatacept
Deaths25
SAEs3135
Treatment-related SAEs512
SAEs Leading to Discontinuation814
AEs493470
Treatment-related AEs204210
AEs Leading to Discontinuation1525
SecondaryAnti-TNF Failure Sub-study Double-blind Period: Number of Participants With SAEs, AEs Leading to Discontinuation or Who Died

AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

Time frame:
Day 1 to 56 days after last dose in short-term or first dose in the long-term, whichever occurs first.
Reported as:
Number · participants
Anti-TNF Failure Sub-study Double-blind Period: Number of Participants With SAEs, AEs Leading to Discontinuation or Who Died
participantsSubcutaneous (SC) AbataceptIntravenous (IV) Abatacept
Deaths00
SAEs00
AEs Leading to Discontinuation00
SecondaryDouble-blind Period: Number of Participants With AEs of Special Interest

AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs: all infections,serious infections,and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (prespecified AEs occurring within 1 hr of start of infusion), peri-infusional AEs (prespecified AEs occurring within 24 hrs of the start of infusion), system injection reactions, and local injection site reactions

Time frame:
Day 1 up to 56 days post last dose in short- term period or first dose in the long -term period, whichever occurs first.
Reported as:
Number · participants
Double-blind Period: Number of Participants With AEs of Special Interest
participantsSubcutaneous AbataceptIntravenous Abatacept
Infections234221
Malignancies35
Autoimmune Disorders76
Acute Infusional AEs2016
Peri-infusional AEs5959
Local Injection Site Reactions1918
Systemic Injection Reactions5656
SecondaryDouble-blind Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements

Vital sign measurements were performed for participants before and after infusion/subcutaneous injection of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.

Time frame:
Day 1 through end of short-term period (Day 169)
Reported as:
Number · participants
Double-blind Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements
participantsSubcutaneous AbataceptIntravenous Abatacept
Double-blind Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements00
SecondaryDouble-blind Period: Number of Participants With Hematology Laboratory Test Results Meeting the Criteria for Marked Abnormality

ULN=upper limit of normal; LLN=lower limit of normal; BL= baseline. Marked abnormality criteria: Hemoglobin: \>3 g/dL decrease from BL; hematocrit: \<0.75\*BL; erythrocytes: \<0.75\*BL; platelets: \<0.67\*LLN/\>1.5\*ULN, or if BL\<LLN, use \<0.5\*BL and \<100,000 mm\^3; leukocytes: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN use \<0.8\*BL or \>ULN, or if BL\>ULN, use \>1.2\*BL or \<LLN; neutrophils+bands: \<1.0\*10\^3 c/uL; eosinophils: \>0.750\*10\^3 c/uL; basophils: \>400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750\*10\^3 c/uL/\>7.50\*10\^3 c/uL.

Time frame:
Day 1 through end of short-term period (Day 169)
Reported as:
Number · participants
Double-blind Period: Number of Participants With Hematology Laboratory Test Results Meeting the Criteria for Marked Abnormality
participantsSubcutaneous AbataceptIntravenous Abatacept
Low hemoglobin (LLN=11.5 g/dL); n=729, 71325
Low hematocrit (LLN=34%); n=726, 71324
Low erythrocytes(LLN=3.8 x10*6c/uL);n=729, 71323
Low platelets (LLN=140*10^9 c/L); n=725, 70910
High platelets (ULN=450*10^9 c/L); n=725, 70900
Low leukocytes (LLN= 3.8*10^3 c/uL); n=729, 71362
High leukocytes (ULN = 10.6*10^3 c/uL);n=729, 7132518
Low neutrophils+bands(LLN=1.8*10^3 c/uL);n=730,71300
High eosinophils (ULN= 7*10^3 c/uL); n=730, 7122216
High basophils (ULN= 0.2*10^3 c/uL); n=730, 71200
High monocytes (ULN=1*10^3 c/uL); n=730, 71201
Low lymphocytes (LLN= 0.7*10^3 c/uL);n=730,7124042
High lymphocytes(ULN=4.5*10^3 c/uL);n=730,7124042
SecondaryDouble-blind Period: Number of Participants With Liver Function Laboratory Test Results Meeting the Criteria for Marked Abnormality

Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\*ULN, or if BL\>ULN, use \>3\*BL; aspartate aminotransferase (AST): \>3\*ULN, or if BL\>ULN, use \>4\*BL; alanine aminotransferase (ALT): \>3\*ULN, or if BL\>ULN, use \>4\*BL; G-glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN, use \>3\*BL; bilirubin: \>2\* ULN, or if BL\>ULN, use \>4\*BL; blood urea nitrogen: \>2\* BL; creatinine: \>1.5\*BL

Time frame:
Day 1 through end of short-term period (Day 169)
Reported as:
Number · participants
Double-blind Period: Number of Participants With Liver Function Laboratory Test Results Meeting the Criteria for Marked Abnormality
participantsSubcutaneous AbataceptIntravenous Abatacept
High ALP (ULN=400 U/L); n=730, 71313
High AST (ULN=44 U/L); n=729, 71355
High ALT (ULN=55 U/L);n=729, 7131216
High GGT (ULN=65 U/L); n=730, 713814
High bilirubin (ULN=1.2 mg/dL); n=730, 71310
High blood urea nitrogen (26 mg/dL); n=730, 7132127
High creatinine (ULN=1.5 mg/dL); n=730, 7131930
SecondaryDouble-blind Period: Number of Participants With Electrolyte Laboratory Test Results Meeting the Criteria for Marked Abnormality

Marked abnormality criteria: Sodium: \<0.95\*LLN/\>1.05\*ULN, or if BL\<LLN, use \<0.95\* BL or \>ULN, or if BL\>ULN, use\>1.05\* BL or \<LLN; potassium: \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN, use\>1.1\* BL or \<LLN; chlorine: \<0.9\*LLN/\>1.1\* ULN, or if BL\<LLN, use \<0.9\*BL or \>ULN, or if BL\>ULN, use\>1.1\*BL or \<LLN; calcium: \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN, use \<0.75\*BL or \>ULN, or if BL\>ULN, use\>1.25\* BL or \<LLN; phosphorous: \<0.75\* LLN/\>1.25\*ULN, or if BL\<LLN, use 0.67\*BL or \>ULN, or if BL\>ULN, use\>1.33\* BL or \<LLN

Time frame:
Day 1 through end of short-term period (Day 169)
Reported as:
Number · participants
Double-blind Period: Number of Participants With Electrolyte Laboratory Test Results Meeting the Criteria for Marked Abnormality
participantsSubcutaneous AbataceptIntravenous Abatacept
Low sodium (LLN=135 mEq/L)20
High sodium (ULN=148 mEq/L)00
Low potassium (LLN=3.5 mEq/L)99
High potassium (ULN=5.5 mEq/L)10
Low chlorine (LLN= 96 mEq/L)00
High chlorine (ULN=109 mEq/L)00
Low calcium (LLN=8.4 mg/dL)10
High calcium (ULN=10.6 mg/dL)10
Low phosphorous (LLN=0.8 mg/dL)12
High phosphorous (ULN=5.6 mg/dL)01
SecondaryDouble-blind Period: Minimum Observed Serum Concentration of Abatacept
Time frame:
Days 57, 85, 113, 120, 127, 134, 141, and 169
Reported as:
Geometric mean · µg/mL
Double-blind Period: Minimum Observed Serum Concentration of Abatacept
µg/mLSubcutaneous AbataceptIntravenous Abatacept
Day 57 (n=25, n=16)31.60 ± 21.48323.14 ± 14.008
Day 85 (n=630, n=649)28.30 ± 21.69220.00 ± 13.441
Day 113 (n=44, n=29)26.49 ± 16.56918.76 ± 16.322
Day 120 (n=27)25.10 ± 14.933NA ± NA
Day 127 (n=28)29.16 ± 14.780NA ± NA
Day 134 (n=27)25.10 ± 15.753NA ± NA
Day 141 (n=26, n=26)25.79 ± 14.26418.10 ± 17.717
Day 169 (n=530, n=521)24.91 ± 14.98918.10 ± 17.94
SecondaryAnti-TNF Failure Sub-study Double-blind Period: Minimum Observed Serum Concentration (Cmin) of Abatacept

Serum concentrations of abatacept were analyzed using a validated ELISA. Steady-state trough observed concentration in serum (Cminss) was measured in μg/mL. Samples were obtained on Days 57, 85, 113, 120, 127, 134, 141, and 169.

Time frame:
Days 57, 85, 113, 120, 127, 134, 141, and 169 (ST Period)
Reported as:
Geometric mean · μg/mL
Anti-TNF Failure Sub-study Double-blind Period: Minimum Observed Serum Concentration (Cmin) of Abatacept
μg/mLSubcutaneous (SC) AbataceptIntravenous (IV) Abatacept
Day 57 (n=3,4)25.53 ± 1615.51 ± 25
Day 85 (n=6,9)21.51 ± 2612.50 ± 48
Day 113 (n=6,6)23.14 ± 2711.10 ± 31
Day 120 (n=4)25.75 ± 17NA ± NA
Day 127 (n=3)25.42 ± 9NA ± NA
Day 134 (n=3)25.55 ± 13NA ± NA
Day 141 (n=4,6)20.85 ± 248.34 ± 44
Day 169 (n=5,7)19.66 ± 259.00 ± 53
SecondaryDouble-blind Period: Maximum Observed Serum Concentration of Abatacept
Time frame:
End of infusion on Days 1 and 113 for IV infusion and in the dosing interval of Days 113 to 120 for subcutaneous
Reported as:
Geometric mean · µg/mL
Double-blind Period: Maximum Observed Serum Concentration of Abatacept
µg/mLSubcutaneous AbataceptIntravenous Abatacept
Double-blind Period: Maximum Observed Serum Concentration of Abatacept40.39 ± 30.148222.35 ± 71.920
SecondaryAnti-TNF Failure Substudy Double Blind Period: Geometric Mean Maximum Observed Serum Concentration of Abatacept

Serum concentrations of abatacept were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). Samples were obtained on Days 57, 85, 113, 120, 127, 134, 141, and 169. Cmax was measured in micrograms per milliliter (μg/mL).

Time frame:
End of infusion on Days 1 and 113 for IV infusion and in the dosing interval of Days 113 to 120 for subcutaneous
Reported as:
Geometric mean · μg/mL
Anti-TNF Failure Substudy Double Blind Period: Geometric Mean Maximum Observed Serum Concentration of Abatacept
μg/mLSubcutaneous (SC) AbataceptIntravenous (IV) Abatacept
Anti-TNF Failure Substudy Double Blind Period: Geometric Mean Maximum Observed Serum Concentration of Abatacept35.84 ± 24229.88 ± 26
SecondaryDouble-blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept
Time frame:
Dosing interval between Days 113 and 141 (TAU=28 days)
Reported as:
Geometric mean · µg*h/mL
Double-blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept
µg*h/mLSubcutaneous AbataceptIntravenous Abatacept
Double-blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept5182.37 ± 2854.13639587.08 ± 15444.743
SecondaryAnti-TNF Failure Sub-study Double Blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept

Serum concentrations of abatacept were analyzed using a validated ELISA. AUC(TAU) was measured as μg\*h/mL. Samples for AUC (TAU) were obtained on Days 113, 120, 127, 134, and 141.

Time frame:
Dosing Interval between Days 113 and 141 (TAU=28 days)
Reported as:
Geometric mean · μg*h/mL
Anti-TNF Failure Sub-study Double Blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept
μg*h/mLSubcutaneous (SC) AbataceptIntravenous (IV) Abatacept
Anti-TNF Failure Sub-study Double Blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept4384.80 ± 1734260.55 ± 35
SecondaryDouble-blind Period: Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Responses Over Time by Enzyme Linked Immunoabsorbant Assay (ELISA)

Serum samples from all treated adult participants with active rheumatoid arthritis were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept (anti-ABA) or anti-CTLA4 antibody (anti-CTLA4).

Time frame:
Days 85, and 169 and postvisits on Days 28, 56, and 85
Reported as:
Number · participants
Double-blind Period: Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Responses Over Time by Enzyme Linked Immunoabsorbant Assay (ELISA)
participantsSubcutaneous AbataceptIntravenous Abatacept
Day 85 anti-ABA (n=700, n=682)02
Day 85 anti-CTLA4 (n=705, n=68900
Day 85 total (n=706, n=689)02
Day 169 anti-ABA (n=671, n=648)34
Day 169 anti-CTLA4 (n=681, n=658)24
Day 169 total (n=681, n=658)58
Overall on-treatment visits anti-ABA (n=707, 691)35
Overall on-treatment visits anti-CTLA4 (n=716,702)24
Overall on-treatment visits total (n=716, 702)59
28 days post last dose anti-ABA (n=18, n=25)00
28 days post last dose anti-CTLA4 (n=20, n=27)02
28 days post last dose total (n=20, n=27)02
56 days post last dose anti-ABA (n=19, n=22)00
56 days post last dose anti-CTLA4 (n=19, n=23)11
56 days post last dose total (n=19, n=23)11
85 days post last dose anti-ABA (n=12, n=15)00
85 days post last dose anti-CTLA4 (n=13, n=15)25
85 days post last dose total (n=13, n=15)25
Overall post visits anti-ABA (n=26, n=29)00
Overall post visits anti-CTLA4 (n=28, n=31)37
Overall post visits total (n=28, n=31)37
Overall anti-ABA (n=714, n=698)35
Overall anti-CTLA4 (n=725, n=710)511
Overall total (n=725, n=710)816
SecondaryDouble-blind Period: Time-matched Median Percent Change From Baseline in Levels of Serum C-reactive Protein Over the Short-term Period

C-reactive protein is an acute phase reactant protein that is a clinical marker for rheumatoid arthritis. Time-matched median percent change from baseline= (time-matched baseline value - Post-baseline value)/time-matched baseline value\*100, where the time-matched baseline value represents the median baseline value for only that cohort of participants with measurements available at that visit.

Time frame:
Baseline to Days 15, 29, 57, 85, 113, 141, and 169
Reported as:
Median · percent change
Double-blind Period: Time-matched Median Percent Change From Baseline in Levels of Serum C-reactive Protein Over the Short-term Period
percent changeSubcutaneous AbataceptIntravenous Abatacept
Day 15 (n=720, n=703)34.16 (-11.11 to 58.80)33.74 (-6.24 to 58.41)
Day 29 (n=727, n=711)39.74 (3.83 to 66.99)42.52 (0.42 to 68.66)
Day 57 (n=727, n=711)47.88 (6.84 to 73.53)51.42 (7.53 to 74.95)
Day 85 (n=727, n=711)52.90 (8.70 to 78.25)53.65 (11.05 to 79.42)
Day 113 (n=727, n=711)53.33 (7.09 to 80.29)58.12 (11.21 to 81.26)
Day 141 (n=727, n=711)56.12 (5.28 to 83.24)58.39 (16.14 to 81.52)
Day 169 (n=727, n=711)57.18 (11.18 to 83.28)56.81 (17.92 to 82.70)
SecondaryDouble-blind Period: Number of Participants With Positive Anti-abatacept Responses Over Time by Electrochemiluminescence Immunoassay Among the First 10% of Participants Randomized

An electrochemiluminescence immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; abatacept molecule). Ig and/or Junction (JNCT) category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a postbaseline titer higher than Baseline, or any postbaseline positivity if Baseline value was missing. Trt=treatment.

Time frame:
Days 85, and 169 and postvisits on Days 28, 56, and 85
Reported as:
Number · participants
Double-blind Period: Number of Participants With Positive Anti-abatacept Responses Over Time by Electrochemiluminescence Immunoassay Among the First 10% of Participants Randomized
participantsSubcutaneous AbataceptIntravenous Abatacept
Day 85 CTLA4 + possibly Ig (n=78, n=67)00
Day 85 Ig +/- JNCT (n=78, n=67)00
Day 85 total (n=78, n=67)00
Day 169 CTLA4 + possibly Ig (n=75, n=67)01
Day 169 Ig +/- JNCT (n=75, n=67)00
Day 169 total (n=75, n=67)01
Overall on-TRT CTLA4 + possibly Ig (n=79, 70)01
Overall on-TRT Ig +/- JNCT (n=79, 70)00
Overall on-TRT total (n=79, 70)01
28 days post last dose CTLA4+possibly Ig (n=2,n=2)00
28 days post last dose Ig +/- JNCT (n=2, n=2)00
28 days post last dose Total (n=2, n=2)00
56 days post last dose CTLA4+possibly Ig (n=2,n=2)00
56 days post last dose Ig +/- JNCT (n=2, n=2)00
56 days post last dose total (n=2, n=2)00
85 days post last dose CTLA4+possibly Ig (n=1,n=1)00
85 days post last dose Ig +/- JNCT (n=1, n=1)00
85 days post last dose total (n=1, n=1)00
Overall post visits CTLA4+possibly Ig (n=3, n=2)00
Overall post visits Ig +/- JNCT (n=3, n=2)00
Overall post visits total (n=3, n=2)00
Overall CTLA4+possibly Ig (n=82, n=71)01
Overall Ig +/- JNCT (n=82, n=71)00
Overall total (n=82, n=71)01
SecondaryDouble-blind Period: Number of Participants Seroconverting by Day 169 According to Status (Negative or Positive) at Baseline

Rheumatoid factor (RF) is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process.

Time frame:
Baseline to Day 169
Reported as:
Number · participants
Double-blind Period: Number of Participants Seroconverting by Day 169 According to Status (Negative or Positive) at Baseline
participantsSubcutaneous AbataceptIntravenous Abatacept
Baseline RF negative10693
Baseline RF negative; Day 169 RF positive23
Baseline RF positive586582
Baseline RF positive ; Day 169 RF negative3340
SecondaryOpen-Label LT Period: Number of Participants Achieving ACR 20 Response at Days 169, 729, 1261, and 1821

The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).

Time frame:
Days 169, 729, 1261, 1821
Reported as:
Number · participants
Open-Label LT Period: Number of Participants Achieving ACR 20 Response at Days 169, 729, 1261, and 1821
participantsOpen-Label SC Abatacept Long Term Period
Day 169 (n=1357)1087
Day 729 (n=1187)973
Day 1261 (n=1068)904
Day 1821 (n=421)356
SecondaryOpen-Label LT Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Days 169, 729, 1261, 1821

The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein). ACR 70 is defined similarly with 70% improvements from baseline for tender and swollen joint counts and 3 out of 5 core measures.

Time frame:
Days 169, 729, 1261, 1821
Reported as:
Number · participants
Open-Label LT Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Days 169, 729, 1261, 1821
participantsOpen-Label SC Abatacept Long Term Period
Day 169 ACR 50 (n=1362)724
Day 729 ACR 50 (n=1185)720
Day 1261 ACR 50(n=1069)672
Day 1821 ACR 50 (n=423)277
Day 169 ACR 70 (n=1362)371
Day 729 ACR 70 (n=1186)443
Day 1261 ACR 70 (n=1070)438
Day 1821 ACR 70 (n=425)191
SecondaryOpen-Label LT Period: Mean Change From Baseline in Disease Activity Score in 28 Joints (DAS28) Using C-reactive Protein (CRP) at Days 169, 729, 1261, 1821

The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6. A clinically significant response= decrease in DAS28 score of \>1.2 from baseline.

Time frame:
Days 169, 729, 1261, 1821
Reported as:
Mean · units on a scale
Open-Label LT Period: Mean Change From Baseline in Disease Activity Score in 28 Joints (DAS28) Using C-reactive Protein (CRP) at Days 169, 729, 1261, 1821
units on a scaleOpen-Label SC Abatacept Long Term Period
Day 169 (n=1353)-2.65 (-2.71 to -2.58)
Day 729 (n=1181)-2.94 (-3.01 to -2.86)
Day 1261 (n=1063)-3.09 (-3.17 to -3.00)
Day 1821 (n=413)-3.24 (-3.38 to -3.11)
SecondaryOpen-Label LT Period: Number of Participants Achieving DAS 28 Remission at Days 169, 729, 1261, 1821

The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6.

Time frame:
Days 169, 729, 1261, 1821
Reported as:
Number · participants
Open-Label LT Period: Number of Participants Achieving DAS 28 Remission at Days 169, 729, 1261, 1821
participantsOpen-Label SC Abatacept Long Term Period
Day 169 (n=1355)334
Day 729 (n=1183)411
Day 1261 (n=1064)425
Day 1821 (n=413)169
SecondaryOpen-Label LT Period: Number of Participants Achieving DAS 28 Low Disease Activity (LDA) at Days 169, 729, 1261, 1821

The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6.

Time frame:
Days 169, 729, 1261, 1821
Reported as:
Number · participants
Open-Label LT Period: Number of Participants Achieving DAS 28 Low Disease Activity (LDA) at Days 169, 729, 1261, 1821
participantsOpen-Label SC Abatacept Long Term Period
Day 169 (n=1355)553
Day 729 (n=1183)600
Day 1261 (n=1064)585
Day 1821 (n=413)238
SecondaryOpen-Label LT Period: Number of Participants With HAQ-DI Response at Days 169, 729, 1261, 1821

The disability section of the full HAQ includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. HAQ-DI overall score ranges from a minimum of 0 to a maximum of 3.0. HAQ response was defined as an improvement (reduction) from baseline (Day 1) of at least 0.3 units in the HAQ score.

Time frame:
Days 169, 729, 1261, 1821
Reported as:
Number · participants
Open-Label LT Period: Number of Participants With HAQ-DI Response at Days 169, 729, 1261, 1821
participantsOpen-Label SC Abatacept Long Term Period
Day 169 (n=1364)962
Day 729 (n=1190)853
Day 1261 (n=1068)780
Day 1821 (n=427)315
PrimaryAnti-TNF Failure Sub-Study Double Blind Period : Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Response in Anti-TNF Failure Population

Serum samples from all treated adult participants with active rheumatoid arthritis who were from the Anti-TNF failure population were screened for the presence of drug-specific antibodies using Enzyme Linked Immunoabsorbant Assay (ELISA). The number of participants who had the presence of anti-abatacept antibodies or anti-CTLA-4 antibodies present in their serum are summarized.

Time frame:
Days 85, and 169 and postvisits on Days 28, 56, and 85
Reported as:
Number · participants
Anti-TNF Failure Sub-Study Double Blind Period : Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Response in Anti-TNF Failure Population
participantsSubcutaneous AbataceptIntravenous Abatacept
Day 85 Anti-abatacept (n=8,10)00
Day 85 Anti-CTLA4-T (n=8,10)00
Day 169 Anti-abatacept (n=6,9)00
Day 169 Anti-CTLA4-T(n=6,9)10
Overall Treatment Anti-abatacept (n=8,10)00
Overall on Treatment Anti-CTLA4-T(n=8,10)10
28 days post Anti-abatacept (n=1,1)00
28 days post Anti-CTLA4-T (n=1,1)00
56 days post Anti-abatacept (n=0,1)00
56 days post Anti-CTLA4-T (n=0,1)00
85 days post Anti-abatacept (n=0,1)00
85 days post Anti-CTLA4-T (n=0,1)00
SecondaryOpen-Label LT Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, or AEs Leading to Discontinuation

AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug

Time frame:
End of ST Period (Day 169) to last dose plus 85 days, up to 5 years (September 2014)
Reported as:
Number · participants
Open-Label LT Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, or AEs Leading to Discontinuation
participantsOpen-Label SC Abatacept Long Term Period
Death41
SAE353
Treatment-related SAE88
SAEs leading to Discontinuation73
Treatment-related AEs632
AEs leading to Discontinuation97
SecondaryOpen-Label LT Period: Number of Participants With AEs of Special Interest

AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs: all infections, serious infections, and opportunistic infections; autoimmune disorders; malignancies; system injection reactions, and local injection site reactions.

Time frame:
End of ST Period (Day 169) to last dose plus 85 days, up to 5 years (September 2014)
Reported as:
Number · participants
Open-Label LT Period: Number of Participants With AEs of Special Interest
participantsOpen-Label SC Abatacept Long Term Period
All Infections962
Serious Infections85
Infections leading to Discontinuation25
Serious Infections leading to Discontinuation16
Malignancies56
Autoimmune Disorders67
Local Injection Site Reactions33
Systemic Injection Reactions161
SecondaryOpen-Label LT Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements

Vital sign assessments were performed in the LT period at 12-week intervals and at a yearly visit (at 16-week intervals) and, for participants who withdrew from the study prematurely, 7 days after the last dose of SC abatacept. Vital signs included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.

Time frame:
End of ST Period (Day 169) to last dose plus 7 days, up to 5 years (September 2014)
Reported as:
Number · participants
Open-Label LT Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements
participantsOpen-Label SC Abatacept Long Term Period
Open-Label LT Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements0
SecondaryOpen-Label LT Period: Number of Participants With Clinically Significant Laboratory Abnormalities

Laboratory assessments were performed in the LT period at 12-week intervals and at a yearly visit and, for participants who withdrew from the study prematurely, 7 days after the last dose of SC abatacept. Abnormalities were determined to be clinically significant by the investigator.

Time frame:
End of ST Period (Day 169) to last dose plus 7 days, up to 5 years (September 2014)
Reported as:
Number · participants
Open-Label LT Period: Number of Participants With Clinically Significant Laboratory Abnormalities
participantsOpen-Label SC Abatacept Long Term Period
Open-Label LT Period: Number of Participants With Clinically Significant Laboratory Abnormalities0

Adverse events

Collected over First dose (Day 1) in ST period to last dose in LT period plus 85 days, up to 5 years (September 2014).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Abatacept—206/731 (28.2%)544/731 (74.4%)
SC Abatacept—199/744 (26.7%)567/744 (76.2%)
Most frequent serious events
Showing 10 of 347
Most frequent serious events
EventIV AbataceptSC Abatacept
OsteoarthritisMusculoskeletal and connective tissue disorders12/73116/744
Rheumatoid arthritisMusculoskeletal and connective tissue disorders12/73114/744
PneumoniaInfections and infestations12/7318/744
Myocardial infarctionCardiac disorders5/73111/744
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)7/7312/744
Urinary tract infectionInfections and infestations7/7311/744
Chest painGeneral disorders6/7314/744
DyspnoeaRespiratory, thoracic and mediastinal disorders2/7316/744
Acute myocardial infarctionCardiac disorders1/7315/744
CholelithiasisHepatobiliary disorders4/7312/744
Most frequent other events
Showing 10 of 20
Most frequent other events
EventIV AbataceptSC Abatacept
Urinary tract infectionInfections and infestations133/731150/744
NasopharyngitisInfections and infestations143/731149/744
Upper respiratory tract infectionInfections and infestations131/731130/744
BronchitisInfections and infestations120/731109/744
HypertensionVascular disorders85/73196/744
DiarrhoeaGastrointestinal disorders89/73196/744
HeadacheNervous system disorders88/73186/744
PharyngitisInfections and infestations80/73174/744
NauseaGastrointestinal disorders53/73179/744
Back painMusculoskeletal and connective tissue disorders76/73176/744

Baseline characteristics

Per-protocol Population in ST Period.

Age, Continuous
Age, Continuous(years)Subcutaneous (SC) AbataceptIntravenous (IV) AbataceptTotal
Mean49.9 ± 13.049.9 ± 12.749.9 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Subcutaneous (SC) AbataceptIntravenous (IV) AbataceptTotal
Female5865491135
Male110134244
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Subcutaneous (SC) AbataceptIntravenous (IV) AbataceptTotal
American Indian or Alaska Native516
Asian6372135
Native Hawaiian or Other Pacific Islander000
Black or African American262450
White5165051021
More than one race000
Unknown or Not Reported8681167
Region Of Enrollment
Region Of Enrollment(participants)Subcutaneous (SC) AbataceptIntravenous (IV) AbataceptTotal
North America129111240
South America338340678
Europe123123246
Rest of the World106109215
Baseline Weight Category
Baseline Weight Category(participants)Subcutaneous (SC) AbataceptIntravenous (IV) AbataceptTotal
<60 kg175171346
60 to 100 kg464465929
>100 kg5747104
Duration of RA Disease
Duration of RA Disease(years)Subcutaneous (SC) AbataceptIntravenous (IV) AbataceptTotal
Mean7.6 ± 8.07.7 ± 7.97.7 ± 7.9
Duration of Disease Category
Duration of Disease Category(participants)Subcutaneous (SC) AbataceptIntravenous (IV) AbataceptTotal
≤2 Years229206435
2 - ≤5 yrs144145289
5 - ≤10 yrs134155289
> 10 yrs189177366
Number of Tender Joints
Number of Tender Joints(tender joints)Subcutaneous (SC) AbataceptIntravenous (IV) AbataceptTotal
Mean30 ± 14.129.2 ± 13.129.6 ± 13.6

10 further baseline measures are reported on the registry.

08

Study locations

204 sites
  • Rheumatology Associates, Pc
    Birmingham, Alabama 35205, United States
  • Coastal Clinical Research, Inc
    Mobile, Alabama 36608, United States
  • Advanced Arthritis Care & Research
    Scottsdale, Arizona 85258, United States
  • Catalina Pointe Clinical Research, Inc.
    Tucson, Arizona 85704, United States
  • St. Joseph'S Mercy Clinic
    Hot Springs, Arkansas 71913, United States
  • Talbert Medical Group
    Huntington Beach, California 92646, United States
  • Allergy & Rheumatology Medical Clinic, Inc.
    La Jolla, California 92037, United States
  • Valerius Medical Group &Research Ctr. Of Greater Long Beach
    Long Beach, California 90806, United States
  • Stanford University School Of Medicine
    Palo Alto, California 94304, United States
  • San Diego Arthritis Medical Clinic
    San Diego, California 92108, United States
  • Boulder Medical Center
    Boulder, Colorado 80304, United States
  • Arthritis Assoc And Osteo Ctr Of Col Sprgs
    Colorado Springs, Colorado 80910, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230, United States
  • Arthritis Center Of The Rockies, Pc
    Loveland, Colorado 80538, United States
  • Guadagnoli, Germano
    Bridgeport, Connecticut 06606, United States
  • Joao Nascimento
    Bridgeport, Connecticut 06606, United States
  • Clinical Research Center Of Ct/Ny
    Danbury, Connecticut 06810, United States
  • Arthritis And Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Arthritis & Osteoporosis Treatment Center, Pa
    Orange Park, Florida 32073, United States
  • Rheumatology Associates Of Central Florida
    Orlando, Florida 32806, United States
  • The Arthritis Center
    Palm Harbor, Florida 34684, United States
  • Sarasota Arthritis Research Center
    Sarasota, Florida 34239, United States
  • Arthritis & Rheumatology Of Georgia,Pc
    Atlanta, Georgia 30342, United States
  • Boise Rheumatology/ Intermountain Research Center, Inc
    Boise, Idaho 83702, United States
  • Coeur D'Alene Arthrit Clin
    Coeur D Alene, Idaho 83814, United States
  • Quincy Medical Group
    Quincy, Illinois 62301, United States
  • Rockford Orthopedic Associates, Ltd.
    Rockford, Illinois 61107, United States
  • The Arthritis Center
    Springfield, Illinois 62704, United States
  • Klein And Associates, M.D., Pa
    Cumberland, Maryland 21502, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01610, United States
  • Shores Rheumatology, P. C.
    St. Clair Shores, Michigan 48081, United States
  • Arthritis Assoicates Of Mississippi
    Jackson, Mississippi 39202, United States
  • Kansas City Internal Medicine
    Lee'S Summit, Missouri 64086, United States
  • Physician Research Collaboration, Llc
    Lincoln, Nebraska 68516, United States
  • Allergy And Arthritis Associates
    Dover, New Jersey 07801, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Albuquerque Rehabilitation & Rheumatology Pc
    Albuquerque, New Mexico 87102, United States
  • The Center For Rheumatology, Llp
    Albany, New York 12206, United States
  • Southern Tier Arthritis & Rheumatism
    Olean, New York 14760, United States
  • Arthritis Health Associates
    Syracuse, New York 13210, United States
  • Asheville Rheumatology & Osteoporosis Research Asso P. A.
    Asheville, North Carolina 28801, United States
  • The Arthritis Clinic & Carolina Bone & Joint
    Charlotte, North Carolina 28210, United States
  • Rheumatology
    Durham, North Carolina 27704, United States
  • Physicians East, Pa
    Greenville, North Carolina 27834, United States
  • Carolina Pharmaceutical Research
    Statesville, North Carolina 28625, United States
  • Carolina Arthritis Associates
    Wilmington, North Carolina 28401, United States
  • Cincinnati Rheumatic Disease Study Group
    Cincinnati, Ohio 45219, United States
  • Health Research Of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Oklahoma Center For Arthritis Therapy And Research
    Tulsa, Oklahoma 74104, United States
  • Healthcare Research Consultants
    Tulsa, Oklahoma 74135, United States
  • Pro Research
    Eugene, Oregon 97401, United States
  • Portland Rheumatology Clinic, Llc
    Lake Oswego, Oregon 97035, United States
  • East Penn Rheumatology Associates
    Bethlehem, Pennsylvania 18015, United States
  • Rheumatology Associates
    Providence, Rhode Island 02906, United States
  • Low Country Rheumatology, Pa
    Charleston, South Carolina 29406, United States
  • Columbia Arthritis Center
    Columbia, South Carolina 29204, United States
  • Carolina Health Specialists
    Myrtle Beach, South Carolina 29572, United States
  • Acme Research, Llc
    Orangeburg, South Carolina 29118, United States
  • Arthritis Clinic
    Jackson, Tennessee 38305, United States
  • Rheumatology Consultants Pllc
    Knoxville, Tennessee 37909, United States
  • The Arthritis Group, Pc
    Memphis, Tennessee 38104, United States
  • St. Thomas Hospital Tower East
    Nashville, Tennessee 37205, United States
  • Walter F. Chase
    Austin, Texas 78705, United States
  • Rheumatic Disease Clinical Research Center, Llc
    Houston, Texas 77004, United States
  • Accurate Clinical Research
    Houston, Texas 77034, United States
  • Texas Research Center
    Sugarland, Texas 77479, United States
  • Arthritis Clinic Of Northern Virginia, P.C.
    Arlington, Virginia 22205, United States
  • Center For Arthritis & Rheumatic Diseases, Pc
    Chesapeake, Virginia 23320, United States
  • South Puget Sound Clinincal Research Center
    Olympia, Washington 98502, United States
  • Tacoma Center For Arthritis Research Ps
    Tacoma, Washington 98405, United States
  • Local Institution
    Ciudad Autonoma, Buenos Aires CP1425A WC, Argentina
  • Local Institution
    Rosario, Santa Fe, Santa Fe 2000, Argentina
  • Local Institution
    Buenos Aires, 1015, Argentina
  • Local Institution
    Buenos Aires, 1426, Argentina
  • Local Institution
    Buenos Aires, C1428DQG, Argentina
  • Local Institution
    Cordoba, 5000, Argentina
  • Local Institution
    Cordoba, 5016, Argentina
  • Local Institution
    Santa Fe, 3000, Argentina
  • Local Institution
    Tucuman, 4000, Argentina
  • Local Institution
    St Leonards, New South Wales 2065, Australia
  • Local Institution
    Cairns, Queensland QLD 4870, Australia
  • Local Institution
    Maroochydore, Queensland 4558, Australia
  • Local Institution
    Woodville, South Australia 5011, Australia
  • Local Institution
    Heidelberg, Victoria 3081, Australia
  • Local Institution
    Shenton Park, Western Australia 6008, Australia
  • Local Institution
    Bruxelles, 1020, Belgium
  • Local Institution
    Bruxelles, 1200, Belgium
  • Local Institution
    Hasselt, 3500, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    Wilrijk, 2610, Belgium
  • Local Institution
    Yvoir, 5530, Belgium
  • Local Institution
    Goiania, Goias 74110, Brazil
  • Local Institution
    Goiania, Goias 74605, Brazil
  • Local Institution
    Juiz De Fora, Minas Gerais 36010, Brazil
  • Local Institution
    Curitiba, Parana 80060240, Brazil
  • Local Institution
    Curitiba, Parana 80440, Brazil
  • Local Institution
    Recife, Pernambuco 50670, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 90035003, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 91610, Brazil
  • Local Institution
    Campinas, Sao Paulo 13059, Brazil

Showing the first 100 of 204 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Alten R, Bingham CO 3rd, Cohen SB, Curtis JR, Kelly S, Wong D, Genovese MC. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet Disord. 2016 May 26;17:231. doi: 10.1186/s12891-016-1082-z. PubMed 27229685 ↗
  • Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Delaet I, Teng J, Alten R. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. J Rheumatol. 2014 Apr;41(4):629-39. doi: 10.3899/jrheum.130112. Epub 2014 Mar 1. PubMed 24584926 ↗
  • Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Porawska W, Box J, Legerton C 3rd, Nasonov E, Durez P, Aranda R, Pappu R, Delaet I, Teng J, Alten R. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011 Oct;63(10):2854-64. doi: 10.1002/art.30463. PubMed 21618201 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Nov 2009 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2007
First posted
Nov 16, 2007
Start
Jan 2008
Primary completionActual
Nov 2009
CompletionActual
Sep 2014
Results first posted
Jul 6, 2011
Last update
Nov 9, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00559585
Responsible party
Sponsor
First posted
Nov 16, 2007
Start date
Jan 2008
Primary completion
Nov 2009
Completion
Sep 2014
Results posted
Jul 6, 2011
Last update
Nov 9, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion